Verve Therapeutics Inc at Cowen Health Care Conference (Virtual) Transcript

Mar 08, 2022 / 02:10PM GMT
Anvita Gupta - TD Cowen, Research Division - Research Associate

Good morning, everyone. I'm Anvita Gupta from Cowen's biotech research team. It is my pleasure to introduce Verve Therapeutics for a formal presentation. Verve is making great strides at developing gene editing medicines to treat cardiovascular diseases with the lead program targeting heterozygous familial hypercholesterolemia. Here with us today is Verve's Co-founder and CEO, Sek Kathiresan. We have a little question and answer around at the end, if we have some time. (Operator Instructions)

With that, Sek, the floor is all yours.

Sekar Kathiresan - Verve Therapeutics, Inc. - Co-Founder, CEO & Director

Thank you very much, Anvita. Really a pleasure to be here. I appreciate the invitation from the Cowen team. So I'm going to share with you the story of Verve Therapeutics. We're looking to transform the treatment of cardiovascular disease from chronic management to single-course gene editing medicines. How are we going to do that? Here are 6 items that really highlight our differentiated

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot